SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025
Protective role of irisin on bone in osteoporosis: a systematic review of rodent studies.
Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Irisin treatment counteracts bone loss and muscle atrophy in aged mice by reducing sclerostin expression in bone and skeletal muscle.Journal of translational medicine · 2026Article
- Musculoskeletal Assessment in Patients with Adrenal Incidentalomas: Should We Integrate the Trabecular Bone Score and/or Circulating Irisin?Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Osteoporosis is defined as a bone disease that is characterized by a reduction in bone mass and an elevated risk of fracture. Irisin, which is regulated by peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α), is a muscle-derived protein that is induced by exercise. A number of studies have indicated that irisin has the capacity to stimulate bone formation and decrease bone resorption, which plays a crucial role in bone metabolism. Regular exercise has been demonstrated to be an effective method for maintaining and enhancing bone health, with irisin emerging as a key regulatory molecule in this process. In light of these findings, irisin represents a promising approach for the treatment of osteoporosis. Animal studies are an essential part of the clinical trial process, as they are used to assess the efficacy and potential risks associated with proposed interventions. The objective of this review was to conduct a systematic review of animal studies and discuss the effects and mechanisms of irisin on bone in osteoporosis. A systematic search was conducted across eight databases, resulting in the identification, data extraction, and quality assessment of 27 articles. The results demonstrate that irisin can restore the steady state of bone homeostasis through the activation or inhibition of multiple pathways. It can ameliorate the microstructural damage and bone turnover caused by osteoporosis; improve the response to bone mechanical stress; promote the proliferation, differentiation, and mineralization of osteoblasts; and play an important role in exercise-based prevention and treatment of osteoporosis. Furthermore, irisin can attenuate inflammatory changes in bone and participate in the regulation of cell death. This review was registered at PROSPERO (CRD42024539678).
Indexed as
Identifiers
40192854What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.